About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do...
TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months
Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade. Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness. The bicaval...
Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?
Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and quality of life. However, researchers are yet to determine the benefit of early intervention in patients presenting intermittent claudication, and whether it improves quality of life. At present, there is little information in this regard (CLEVER trial), and...
Thanks everyone for making part of Paraguay SOLACI Sessions 2022!
We have reached the end of SOLACI Sessions 44th edition. We have enjoyed 2 days of intense scientific activities with multiple educational symposia, case study discussions, theoretical and practical approaches to issues of interest in interventional cardiology and fruitful knowledge exchange between prestigious colleagues from Paraguay and Latin America. With over 200 registered attendees and...
The Latin American Group of Interventionist Women Performed 4 TAVR Cases in Paraguay
The MIL-SOLACI continues to grow and keeps developing activities to foster integration and women’s participation all across Latin America. IN this opportunity, and for the first time, the area directed by Dr. Carla Agatiello (ARG) performed 4 transcatheter aortic valve implantations (TAVR) at the National University’s Clinical Hospital of Asunción, in Paraguay. The interventions, performed...
Safety of Acetylcholine in the Cath Lab
The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery disease (MINOCA) have been established, widely spread, accepted, and included in the different guidelines that support our clinical practice. Among INOCA and MINOCA we find vasospastic angina (VSA) caused by epicardial vessel spasms and angina caused by microvascular...
TAVR, More Information Supports Its Use
TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving...
Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?
Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise....
EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation
At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results. The aim of this multicenter, prospective study was to assess the safety and efficacy of the...
EuroPCR 2022 | TriCLASP, Evolution at 30 Days
Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low. Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patients...